An important aspect of our center's research are medical treatment studies, called clinical trials. These studies provide a controlled and monitored environment where volunteer research participants can safely take experimental medication. Most of the trials at our center are placebo-controlled, double-blind studies, meaning that there is a chance that participants will be on the experimental medication or on a placebo (a substance that looks the same but contains no medication).

On this page, you will find basic information about the clinical trials for which we are currently enrolling. In general, calling us is the best way to find out if you or a loved one is eligible for a study.

A note about the location of our studies:
Our center is located at the Seattle VA Puget Sound location, however for some of our studies we are able to see participants at the Tacoma (American Lake) VA Puget Sound location. If you have any questions, contact us at 206.764.2069 or 1.800.317.5382.

Currently Enrolling Studies


A4_for_website.png

A4 Trial: Anti-Amyloid Treatment in Asymptomatic Alzhiemer's Disease

Key Researcher: Elaine Peskind, MD
Study Coordinator: Anita Ranta
Study Contact Number:
206.764.2069 or 1.800.317.5382

More information about the study; Study Flyer; Study Brochure

Study Overview

This three-year study will evaluate a new drug that may reduce the impact of Alzheimer’s-related protein plaques in individuals at risk for developing the disease. Scientists believe that the slow accumulation of these neurotoxic amyloid plaques in the brain over many years may cause Alzheimer’s disease (AD) to begin developing long before symptoms appear. Thus, this study will enroll people between the ages of 65 and 85 with normal thinking and memory functioning but with evidence of amyloid plaque buildup in the brain. Half of the participants will receive the study drug while the other half will receive a substance that has no active ingredients in it. Each participant will visit the study site once a month for an intravenous infusion of the study drug or placebo. An extension study may be available at the conclusion that allows everyone to take the study drug.


WhiteManMaleDoctor.jpg

LZAX Study: Solanezumab for the Treatment of Mild Alzheimer’s

Disease

Key Researcher: Elaine Peskind, MD
Study Coordinator: Anita Ranta
Study Contact Number:
206.764.2069 or 1.800.317.5382

Study Overview

The purpose of this study is to see if an investigational drug, solanezumab, is safe and effective in the treatment of mild Alzheimer’s disease. The study is sponsored by Eli Lilly and Company. Approximately 1850 subjects with Alzheimer’s disease have received solanezumab in prior studies conducted by the sponsor. Subjects will receive either solanezumab or placebo (a substance that looks the same but has no active drug in it). The study drug is given through an intravenous infusion (sometimes called an “IV” or a “drip”) over about 30 minutes.  The study lasts 18 months with visits every four weeks to the research center at the VA Puget Sound in Seattle. The study is open to members of the public. Research participants may be taking other FDA approved medications for Alzheimer’s disease and still enroll in this study.


Accera_Nourish_AD_Logo.png

NOURISH AD Study

Key Researcher: Elaine Peskind, MD
Study Coordinator: Anita Ranta
Study Contact Number:
206.764.2069 or 1.800.317.5382
Study Flyer

Study Overview

In this multi-site, nationwide study, we are taking a look at an investigational medication that may improve thinking and memory in individuals with mild to moderate Alzheimer’s disease. In many cases, as Alzheimer’s disease progresses, some areas of the brain become less efficient at converting glucose to energy. The investigational medication in this study, AC-1204, increases the production of ketone bodies. Ketone bodies can act as an alternative brain fuel for patients with Alzheimer’s disease.


DOD_ADNI_image.png

Department of Defense Alzheimer's Disease Neuroimaging Initiative (DOD ADNI) Study for Vietnam Era Veterans

ADRC Key Researcher: Elaine Peskind, MD
National Study Coordinator: Jaqueline Hays
National Study Contact Number:
1.800.773.4883
Study Flyer
; Study Website

Study Overview

Traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) are common combat related problems and may be associated with a greater risk of Alzheimer’s disease. The purpose of this study is to examine the possible connections between TBI and PTSD, and the signs and symptoms of Alzheimer’s disease on Veterans as they age. The information we collect will help us to learn more about how these injuries may affect Veterans of the Vietnam War as they grow older, as well as Veterans of the current wars in Iraq and Afghanistan, who also have these types of combat related injuries.


 Continuing Studies (Not Currently Enrolling)


Even after a study has stopped enrolling subjects, the work still continues. Often, our researchers follow participants in studies for a continued period of time after the study has closed enrollment, monitoring the effects of experimental medications and the changes occurring throughout the study. The studies we are continuing at our center are listed below.


Currently Enrolling Studies - UW School of Nursing

Early Stage Memory Loss Study

Key Researcher: Rebecca Logsdon, PhD
Study Coordinator: Amy Cunningham, MS.
Study Contact Number: 206.616.5550 or 1.866.292.4464
Study Flyer

Study Overview

This investigation evaluates the comparative efficacy of two non-pharmacologic interventions developed by Dr. Logsdon and colleagues to improve quality of life, mood, social, and physical well-being of individuals with early stage Alzheimer’s disease and related disorders and their family care partners.    Participants are randomly assigned to one of three groups: Social Activity Program, Exercise Activity Program, or Control Group.  The programs meet weekly for four weeks. Control group participants can choose to attend either program after their final four month interview.   Programs are held throughout Western Washington.  Three interviews are done in participant’s home.  


Reducing Disabilities in Alzheimer's Disease (RDAD) Translation in Area Agencies on Aging  

Key Researchers: Linda Teri, PhD., Rebecca Logsdon, PhD., Susan McCurry, PhD., Jurgen Unutzer, MD., Sean Sullivan, Ph.D.
Study Coordinator: Amy Cunningham, MS
Study Contact Number:
206.616.5550 or 1.866.292.4464
Study Flyer

Study Overview

The University of Washington's Northwest Research Group on Aging is partnering with Area Agencies on Aging (AAA) in Washington and Oregon to complete this translational investigation of RDAD (Reducing Disabilities in Alzheimer's Disease).  RDAD is an evidence-based program with demonstrated efficacy in helping older adults with dementia maintain physical function and remain physically and mentally healthy. Coaches from eight AAAs have been trained to provide the RDAD program throughout their communities. The coaches provide exercise instruction to both the individual with dementia and their care partner, and behavior management techniques to the care partner.  All coach sessions are done in the home and study interviews are done by telephone.